| Literature DB >> 32672371 |
Sarah Vossoughi1, Katherine Fischkoff2, Robert A DeSimone3, Joseph Schwartz1.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32672371 PMCID: PMC7404962 DOI: 10.1111/trf.15995
Source DB: PubMed Journal: Transfusion ISSN: 0041-1132 Impact factor: 3.337
Transfusion medicine echelons of care
| Situation | Response |
|---|---|
|
| |
| Standard supply and utilization (preventative measures only) | Prospective audit and transfusion medicine physician approval required for: Orders exceeding transfusion guidelines Second dose of blood product within 24 h Hospital leadership to limit elective (nonurgent) procedures |
|
| |
| Incoming shipment decreased 50% | Conservative management: Semielective procedures with high likelihood of transfusion require review/approval by hospital leadership (eg, transplant) Split platelet products into smaller doses Encourage nontransfusion approaches (ie, antifibrinolytics) |
|
| |
| Incoming shipment decreased 75% | Aggressive mitigation: Cancel bone marrow and liver transplants Platelets for active bleeding only Lower hemoglobin transfusion thresholds in nonbleeding patients |
|
| |
|
<10% inventory remains or Unable to maintain minimal staffing | Crisis plan: All products for active bleeding only All products emergency release only (no pretransfusion testing) Lower hemoglobin transfusion threshold for ECMO Prospective audit of all massive hemorrhage activations (First round of blood products released, followed by a multidisciplinary goals of care discussion with treatment team) |
ECMO, extracorporeal membrane oxygenation.